CHANGZHOU, China, Jan. 17, 2025 /PRNewswire/ -- EZGO Technologies Ltd. (NASDAQ:EZGO) ("EZGO" or "we", "our", or the "Company"), a leading short-distance transportation solutions provider in China, today announced its audited financial results for the fiscal year ended September 30, 2024 (the "Fiscal Year 2024"). Fiscal Year 2024 Financial Highlights (all results compared to the prior year period unless otherwise noted) Revenues were $21.1 million, an increase of 32.7%, which was primarily due to the increase of sales of battery packs resulting from the increased acceptance of our lithium battery packs in the market.Gross profit was $1.5 million, an increase of 32.5%. Gross margin was 7.1%,

The Board of Directors of Sensient Technologies Corporation (NYSE:SXT) has declared a regular quarterly cash dividend on its common stock of $0.41 per share. The cash dividend will be paid on March 3, 2025, to shareholders of record on February 4, 2025. About Sensient Technologies Sensient Technologies Corporation is a leading global manufacturer and marketer of colors, flavors, and other specialty ingredients. Sensient uses advanced technologies and robust global supply chain capabilities to develop specialized solutions for food and beverages, as well as products that serve the pharmaceutical, nutraceutical, and personal care industries. Sensient's customers range in size from small e

First approval in the US for AstraZeneca and Daiichi Sankyo's DATROWAY based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death vs. chemotherapy DATROWAY is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030 DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. The approval by the US Food and Drug Administration (FDA) was based on results from th

First approval in the U.S. for Daiichi Sankyo and AstraZeneca's DATROWAY based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death versus chemotherapy Second DXd antibody drug conjugate approved in U.S. based on Daiichi Sankyo's DXd technology DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug

Morgan Stanley reiterated coverage of Robinhood Markets with a rating of Overweight and set a new price target of $64.00 from $55.00 previously

Deutsche Bank downgraded argenx from Hold to Sell

H.C. Wainwright downgraded CECO Environ. from Buy to Neutral

BofA Securities upgraded Toronto-Dominion Bank from Neutral to Buy

4 - OPKO HEALTH, INC. (0000944809) (Issuer)

4 - NUVEEN MUNICIPAL HIGH INCOME OPPORTUNITY FUND (0001266585) (Issuer)

4 - Nuveen Quality Municipal Income Fund (0001083839) (Issuer)

4 - CHEMUNG FINANCIAL CORP (0000763563) (Issuer)

4 - Phreesia, Inc. (0001412408) (Issuer)

4 - Third Harmonic Bio, Inc. (0001923840) (Issuer)

4 - REPUBLIC SERVICES, INC. (0001060391) (Issuer)

4 - Concrete Pumping Holdings, Inc. (0001703956) (Issuer)

SCHEDULE 13D/A - Symbotic Inc. (0001837240) (Subject)

DEF 14A - Oaktree Specialty Lending Corp (0001414932) (Filer)

PRE 14A - Eastside Distilling, Inc. (0001534708) (Filer)

S-1 - Kiromic Biopharma, Inc. (0001792581) (Filer)

For Immediate Release: December 13, 2024 Today, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) to be used together with glucocorticoids (steroids) to control androgen (a testosterone-like hormone) levels in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).“Today’s approval provides an important advance for patients with classic con

For Immediate Release: December 06, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA published the draft guidance, “Expedited Program for Serious Conditions — Accelerated Approval of Drugs and Biologics,” which proposes updates to certain agency policies and procedures regarding accelerated approval. Topics addressed by this

Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

WESTMINSTER, MA / ACCESS Newswire / January 17, 2025 / TechPrecision Corporation (NASDAQ:TPCS) ("TechPrecision" or "the Company"), today announced that John A. Moore resigned as a member of the board of directors (the "Board") of the Company, effective on January 13, 2025 to focus on his other responsibilities. The Board has decided not to fill the vacancy created by Mr. Moore's resignation at this time. As a result of Mr. Moore's resignation, the composition of the committees of the Board has changed as follows:Audit Committee: Walter M. Schenker (Chair), Andrew A. Levy and General Victor E. Renuart Jr.Compensation Committee: Andrew A. Levy (Chair) and Robert D. StrausAbout TechPrecision Co

Deal Will Expand PepsiCo's Food Portfolio to Include More Options for Consumers Looking for Positive Choices and Simple Ingredients PURCHASE, N.Y. and AUSTIN, Texas, Jan. 17, 2025 /PRNewswire/ -- PepsiCo, Inc. (NASDAQ:PEP) ("PepsiCo") today announced that it has closed the acquisition of Garza Food Ventures LLC, dba Siete Foods ("Siete"), for $1.2 billion.  Over the past two decades, PepsiCo has transformed its portfolio to include great-tasting convenient foods and drinks that are nutritious, enjoyable, and fit consumers' lifestyles. The company continues to expand positive c

Sturm, Ruger & Company, Inc. (NYSE:RGR) is pleased to announce the appointment of Todd W. Seyfert as its next President and Chief Executive Officer, effective March 1, 2025. Mr. Seyfert brings to Ruger a distinguished track record of driving corporate growth, profitability, and operational excellence across multiple manufacturing enterprises. John A. Cosentino, Jr., Chairman of the Board of Directors, noted, "Todd is an accomplished executive with extensive experience in the outdoor adventure and shooting sports industries, and well recognized for his leadership, strategic vision, and operational expertise. He will be instrumental in further strengthening Ruger's market position and deliv

RENO, Nev., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Plumas Bancorp (NASDAQ:PLBC), the bank holding company and the parent company of Plumas Bank, recently announced the appointment of Kevin Foster to its Board of Directors, effective January 15, 2025. Foster retired in 2023 after a distinguished 40-year career in banking and technology. His most recent position was at Ernst & Young, one of the largest professional services organizations in the world. His expertise lies in various aspects of banking including lending, technology, cybersecurity, data, consulting, and sales, with a focus on driving transformation, efficiency, and compliance. Foster holds a Bachelor of Science degree in Finance from

CHANGZHOU, China, Jan. 17, 2025 /PRNewswire/ -- EZGO Technologies Ltd. (NASDAQ:EZGO) ("EZGO" or "we", "our", or the "Company"), a leading short-distance transportation solutions provider in China, today announced its audited financial results for the fiscal year ended September 30, 2024 (the "Fiscal Year 2024"). Fiscal Year 2024 Financial Highlights (all results compared to the prior year period unless otherwise noted) Revenues were $21.1 million, an increase of 32.7%, which was primarily due to the increase of sales of battery packs resulting from the increased acceptance of our lithium battery packs in the market.Gross profit was $1.5 million, an increase of 32.5%. Gross margin was 7.1%,

The Board of Directors of Sensient Technologies Corporation (NYSE:SXT) has declared a regular quarterly cash dividend on its common stock of $0.41 per share. The cash dividend will be paid on March 3, 2025, to shareholders of record on February 4, 2025. About Sensient Technologies Sensient Technologies Corporation is a leading global manufacturer and marketer of colors, flavors, and other specialty ingredients. Sensient uses advanced technologies and robust global supply chain capabilities to develop specialized solutions for food and beverages, as well as products that serve the pharmaceutical, nutraceutical, and personal care industries. Sensient's customers range in size from small e

Alliant Energy Corporation (NASDAQ:LNT) has scheduled its fourth quarter and year end 2024 earnings release for Thursday, February 20th, after market close. A conference call to review the fourth quarter and year end results is scheduled for Friday, February 21st at 9 a.m. CT. Alliant Energy will webcast the event live at www.alliantenergy.com/investors. The call is open to the public and will be hosted by Lisa Barton, President and CEO; and Robert Durian, Executive Vice President and CFO. Individuals who would like to participate in the conference call can do so by dialing (800) 549-8228 (Toll Free – North America) or (289) 819-1520 (International). The conference ID is 45427. An archi

The Alliant Energy Corporation (NASDAQ:LNT) Board of Directors today declared a quarterly cash dividend of $0.5075 per share payable on February 18, 2025, to shareowners of record as of the close of business on January 31, 2025. Dividends on common stock have been paid for 317 consecutive quarters since 1946. Alliant Energy Corporation is recognized as a member of the S&P 500 Dividend Aristocrats Index. Alliant Energy Corporation (NASDAQ:LNT) provides regulated energy service to approximately 1,000,000 electric and 425,000 natural gas customers across Iowa and Wisconsin. Alliant Energy's mission is to deliver energy solutions and exceptional service customers and communities count on

SC 13D/A - CVR ENERGY INC (0001376139) (Subject)

SC 13D/A - INCOME OPPORTUNITY REALTY INVESTORS INC /TX/ (0000949961) (Subject)

SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

SC 13D - Neuronetics, Inc. (0001227636) (Subject)

Recently, on July 4, 2024, a significant insider purchase was recorded at Allied Gaming & Entertainment Inc. as Large owner Choi Roy bought $456,750 worth of shares (360,000 units at $1.27), increasing direct ownership by 14% to 2,871,822 units (SEC Form 4). This purchase is notable for the size of the transaction and the percentage increase in direct ownership, indicating a strong belief in the company's future prospects. Insider purchases are generally viewed positively by investors as they signal confidence from those with intimate knowledge of the company's operations. Examining other recent insider transactions at Allied Gaming & Entertainment Inc., we notice a few patterns worth explo

Recently, on June 25, 2024, Director Romano Kelly A bought $100,051 worth of shares in Athira Pharma Inc. This transaction involved acquiring 42,400 units at $2.36 per share, resulting in a significant increase in direct ownership by 111% to 80,715 units. The purchase was disclosed in the SEC Form 4 filing. Insider buying is often considered a bullish signal as insiders may have insights into the company's future performance. It's essential to analyze this insider purchase in conjunction with previous insider transactions to identify any patterns or trends. Taking into account the information from the SEC filings, several other insiders at Athira Pharma Inc. have also been active in the sto

Recently, on June 26, 2024, Director Juda Scott bought $36,350 worth of shares (5,000 units at $7.27) (SEC Form 4) in INmune Bio Inc. This insider purchase is significant as it indicates confidence from someone within the company towards its future growth prospects. It's interesting to note that this purchase by Juda Scott follows a series of transactions by other insiders in the company. For example, Moss David J bought $149,993 worth of shares (18,028 units at $8.32) on April 24, 2024, increasing direct ownership by 1% to 1,268,179 units. This demonstrates a consistent trend of insider buying within the organization. Looking back at previous transactions, on May 16, 2024, several key ins

Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan